GLP-1 medicines usually improve blood fats a little, and tirzepatide and semaglutide do it most clearly. The biggest and most consistent change is a drop in triglycerides. LDL ("bad") cholesterol falls modestly, HDL ("good") cholesterol rises slightly, and the size of each change depends on the drug, the dose and the person. These drugs are not cholesterol treatments. If your lipids are a concern, the useful step is a lab panel and a conversation with a clinician before, during and after treatment. This guide covers what the trials found, why it happens, what to expect if you stop, and how to prepare for that conversation.
TL;DR
- Triglycerides show the clearest improvement on GLP-1 and GLP-1/GIP medicines. In a 2024 meta-analysis, tirzepatide at 15 mg lowered them by about 22% versus controls.
- LDL changes are smaller and vary by drug. Among single-target GLP-1 drugs, semaglutide was the only one with a significant LDL reduction in a large BMJ analysis.
- Statins remain the first-line lipid-lowering medicine in U.S. cardiology guidelines. GLP-1 medicines are used for diabetes, weight and heart risk, not as a cholesterol replacement.
- After stopping, lipids tend to drift back up, along with weight, so repeat labs matter.
- Ask for a baseline lipid panel and a follow-up one. Your clinician decides what is right for you.
Table of Contents
- What GLP-1 medicines do to your lipid panel
- Tirzepatide and cholesterol
- Why lipids change: weight loss, direct effects, or both?
- GLP-1 medicines are not a replacement for cholesterol medication
- What happens to cholesterol if you stop
- Safety and who should talk to a clinician first
- How to prepare for the conversation
- Promo: a clinician consultation and labs through AirMedFit
- Perspective
- FAQ
- Sources
What GLP-1 medicines do to your lipid panel
A standard lipid panel reports four numbers: total cholesterol, LDL, HDL and triglycerides. GLP-1 receptor agonists (semaglutide, liraglutide and similar drugs) and the dual GIP/GLP-1 agonist tirzepatide were built to lower blood sugar and body weight. Lipid changes come along with them.
The largest comparison so far is a BMJ network meta-analysis of 76 trials covering 15 GLP-1 drugs and 39,246 participants. Compared with placebo:
- Semaglutide was the only GLP-1 drug that significantly lowered LDL (by 0.16 mmol/L) and total cholesterol (by 0.48 mmol/L).
- Tirzepatide significantly lowered triglycerides (by 0.89 mmol/L).
- Only one drug, PEG-loxenatide, significantly raised HDL.
Those numbers are averages across many people. They are small compared with what a statin does to LDL, and they should not be read as a promise for any one person.
A real-world look points the same way. A narrative review in 2024 summarized a retrospective cohort of 1,023 patients in which semaglutide users had drops in total cholesterol (10.3 mg/dL), LDL (5.2 mg/dL) and triglycerides (20.4 mg/dL). Those are modest, average shifts. Your own labs may move more, less or not at all.
Tirzepatide and cholesterol
Tirzepatide activates two receptors (GIP and GLP-1) and tends to produce larger weight loss than single-target drugs. That is one reason people searching for tirzepatide and cholesterol want to know whether the lipid effects are larger too.
A 2024 meta-analysis of 13 tirzepatide trials found effects that rose with the dose. At 15 mg, compared with control groups:
| Lipid measure | Change at 15 mg |
|---|---|
| LDL cholesterol | down 7.82% |
| Total cholesterol | down 6.55% |
| Triglycerides | down 22.08% |
| HDL cholesterol | up 6.94% |
An earlier 2023 meta-analysis of seven trials saw the same direction, with total cholesterol down by a median of 3.76% at 5 mg, 4.63% at 10 mg and 5.93% at 15 mg. A network analysis of 26 trials in people with type 2 diabetes also found lower LDL, triglycerides and total cholesterol than with placebo, insulin or SGLT2 inhibitors.
The picture is not uniform, though. A 2025 review of the phase 3 trial programs reported triglyceride reductions of 12.8% to 26.7% in the SURPASS trials and 8.2% to 31.4% in the SURMOUNT trials. LDL changes ranged from small drops up to 15.5%. In one SURMOUNT trial in people with type 2 diabetes, LDL actually rose 2.9% on tirzepatide, compared with a 7.4% rise on placebo. In other words, the dose, the starting point and the other medicines you take all shape the result.
How does tirzepatide compare with semaglutide? In SURPASS-2, as described in a 2024 review, tirzepatide's effects on triglycerides, VLDL and HDL were greater than semaglutide's. Total cholesterol and LDL did not differ in the same way.
If you want the broader picture of these two drugs, our guides cover what the evidence shows for tirzepatide and what it shows for semaglutide.
Why lipids change: weight loss, direct effects, or both?
Both appear to play a part. Losing body fat improves most lipid markers on its own, so some of the change is simply the result of weight loss. But researchers also see effects that look more direct.
In animal experiments, GLP-1 reduced fat absorption from the gut and slowed the production of chylomicrons (the particles that carry dietary fat into the blood) through a nerve signal from the gut. That work found the effect did not depend on insulin release or on slower stomach emptying. This is laboratory evidence, so it explains plausible mechanisms and does not predict your result.
For heart risk, the story is wider than cholesterol. A 2022 review explains that the cardiovascular benefit seen in GLP-1 outcome trials comes through several pathways, including lower blood pressure, better blood-vessel function and less inflammation, and that weight loss alone does not account for it. For tirzepatide, the authors of the 2024 review say better lipids and blood pressure would be expected to help, but this still needs formal testing in ongoing phase 3 trials.
Practical takeaway: better numbers on a lab report are encouraging, but they are not the same thing as a proven drop in heart attacks for every drug.

GLP-1 medicines are not a replacement for cholesterol medication
If your LDL is high, a GLP-1 medicine is not designed to be the fix. The ACC/AHA chronic coronary disease guideline, summarized by the American Academy of Family Physicians, states that statins are the first-line lipid-lowering medicine. It also says GLP-1 receptor agonists should be considered in people with chronic coronary disease, including those without diabetes.
More recent U.S. guidance keeps the two jobs separate. A 2026 summary in JACC describes the cardiovascular-kidney-metabolic (CKM) statement, which recommends GLP-1-based therapy for adults with stage 2 or 3 CKM syndrome, type 2 diabetes and increased cardiovascular risk (a 10-year PREVENT-CVD risk of 7.5% or more). The same source notes the 2026 dyslipidemia guideline recommends lipid-lowering therapy at a PREVENT-ASCVD risk of 5% or more. PREVENT is a risk calculator from the American Heart Association that estimates your 10-year chance of cardiovascular disease from age, blood pressure, cholesterol, kidney function and other factors.
If you already take a statin or another lipid medicine, do not change or stop it on your own because you start a GLP-1 drug. Your prescriber decides whether the combination suits you.

What happens to cholesterol if you stop
Most people considering these drugs ask what happens when treatment ends. The best data comes from a 2025 Lancet meta-analysis of 18 trials with 3,771 people who had obesity. After discontinuation:
- LDL, total cholesterol, triglycerides and VLDL rose by small but statistically significant amounts.
- Weight returned by an average of 5.63 kg, and HbA1c (a three-month blood sugar marker) rose by 0.25 percentage points.
- In STEP-10, more than 40% of lost weight came back within 28 weeks of stopping semaglutide. In SURMOUNT-4, more than half rebounded over 52 weeks after stopping tirzepatide.
A small two-year study of 25 women with PCOS found total and LDL cholesterol improvements moved back toward baseline after semaglutide ended.
The lesson is not that these medicines stop working. It is that the lipid gains are tied to staying on treatment and to the lifestyle habits you build around it. Plan the exit with your clinician before you start: how long, what monitoring, and what you will do about food and exercise. Our guide to strength training on a GLP-1 covers one habit that helps you keep muscle while you lose weight.
Body changes can also show up in how skin looks after significant weight loss. If that is a concern, there are options for skin tightening after GLP-1 weight loss, which are worth discussing at the point you reach your goal.
Safety and who should talk to a clinician first
Lipid changes are one outcome among many. Before starting, tell your prescriber about pancreatitis, gallbladder disease, thyroid conditions, kidney disease, pregnancy plans and every medicine and supplement you take. Our guides cover common side effects and when to seek care and GLP-1 medicines and hypothyroidism. Also note which version you are considering. FDA-approved products, compounded versions and investigational peptides are different categories, and they carry different levels of evidence. Our pieces on peptides marketed alongside GLP-1 drugs and on a consultation checklist for compounded tirzepatide versus Zepbound explain the difference. Dosing is set by a clinician; we do not publish self-treatment doses.
How to prepare for the conversation
A short, specific plan makes a consultation more useful.
- Get baseline labs. A lipid panel before you start gives you something to compare against. Ask which tests your clinician wants, and whether a fasting sample is needed.
- Gather your history. Bring family history of heart disease, prior lab results, blood pressure readings, and a list of everything you take.
- Ask about your risk. Ask whether your clinician uses a risk calculator such as PREVENT and what your estimate means for statins or other lipid treatment.
- Ask about the product. Is it approved by the FDA, compounded, or something else? What follow-up is included?
- Plan the follow-up. Ask when to repeat labs, what changes would prompt a dose or medicine review, and what the plan is if you stop.
Promo: a clinician consultation and labs through AirMedFit
If you want to take these questions to a clinician online, AirMedFit lists two consultation formats on its Doctor's Consultation page. The Async Doctor's Consult is listed at $49 one-off and the Sync Doctor's Consult at $120 one-off. Whether a treatment is appropriate is decided by the clinician after review, and availability and scope should be confirmed on the page.

AirMedFit also lists home-kit lab panels: the Men's Essential panel at $129 one-off and the Women's Essential panel at $139 one-off. You can see them under medical services, and you can browse the full consultation listing or start from the AirMedFit home page. Confirm what each panel includes before you order.
Perspective
We publish educational information, and the lesson we take from the lipid research is that numbers on a page only help when someone interprets them for you. The trials show that triglycerides improve most reliably, that LDL moves modestly, and that results differ by drug and dose. None of that tells you what your own panel will do.
That is why we think of a consultation as the place to turn the evidence into a plan: which labs to draw first, how your cardiovascular risk looks, whether a statin belongs in the picture, and what follow-up should look like. We list a Doctor's Consultation on our site so you can bring a prepared set of questions to a clinician, and lab panels so a baseline can be on hand for that conversation.
We also think you deserve clear language on products. FDA-approved, compounded and investigational are not interchangeable words, and we encourage you to ask which one you are being offered.
AirMedFit
FAQ
Do GLP-1 medicines lower LDL cholesterol?
Often a little. In a large BMJ analysis, semaglutide was the only single-target GLP-1 drug with a significant LDL drop, and tirzepatide lowered LDL by about 7.8% at 15 mg in a 2024 meta-analysis. Some trials show LDL unchanged or slightly higher, so your own labs are what count.
Can Ozempic or other GLP-1 drugs raise triglycerides?
The trials point the other way: triglycerides are the lipid that falls most consistently on these medicines. Individual results vary, and other factors such as diet, alcohol, diabetes control and other medicines also affect triglycerides. If your levels rise, tell your prescriber.
Can I stop my statin once I start a GLP-1 medicine?
Do not stop a statin without your prescriber's approval. U.S. guidelines still describe statins as the first-line lipid-lowering medicine, and GLP-1 drugs are used for other goals. Your clinician can review your labs and risk and decide.
Will my cholesterol go back up if I stop?
It may. A 2025 meta-analysis of 18 trials found small but significant increases in LDL, total cholesterol and triglycerides after stopping, along with weight regain. Planning follow-up labs and lifestyle habits before you stop gives you the best chance to catch changes early.
Sources
- BMJ network meta-analysis of GLP-1 drugs and lipids
- Narrative review of GLP-1 receptor agonists and lipids (PMC, 2024)
- Effects of tirzepatide on lipid profile: meta-analysis (PMC, 2024)
- Effect of tirzepatide on blood pressure and lipids (Diabetes, Obesity and Metabolism, 2023)
- Lipid profile changes with GLP-1 therapies: network meta-analysis (PubMed)
- Tirzepatide mechanism of action review (PMC, 2025)
- Incretin-based therapies review (PMC, 2024)
- GLP-1 and intestinal fat absorption via vagal nerves (PMC)
- Managing cardiovascular risk in diabetes (PMC, 2022)
- ACC/AHA chronic coronary disease guideline summary (AAFP)
- Predicted risk and expected benefit to guide therapy (JACC, 2026)
- Metabolic rebound after GLP-1 receptor agonist discontinuation (Lancet, 2025)
- Semaglutide discontinuation and weight maintenance in PCOS (PMC, 2024)
Recommended
- GLP-1 for Weight Loss: What the Evidence Actually Shows
- Tirzepatide for Weight Loss: What the Evidence Shows
- Semaglutide for Weight Loss: What the Evidence Shows
- GLP-1 Plateau: How Clinicians Fix a Stall Without Raising Dose
This article provides general educational information and is not personalized medical advice. A licensed clinician should assess treatment suitability, risks, and options.
